Cargando…

Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer

INTRODUCTION: Tumor microenvironment immunity is associated with breast cancer outcome. A high lymphocytic infiltration has been associated with response to neoadjuvant chemotherapy, but the contribution to response and prognosis of immune cell subpopulations profiles in both pre-treated and post-tr...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Martínez, Elena, Gil, Ginés Luengo, Benito, Asunción Chaves, González-Billalabeitia, Enrique, Conesa, María Angeles Vicente, García, Teresa García, García-Garre, Elisa, Vicente, Vicente, de la Peña, Francisco Ayala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303200/
https://www.ncbi.nlm.nih.gov/pubmed/25432519
http://dx.doi.org/10.1186/s13058-014-0488-5
_version_ 1782353904960274432
author García-Martínez, Elena
Gil, Ginés Luengo
Benito, Asunción Chaves
González-Billalabeitia, Enrique
Conesa, María Angeles Vicente
García, Teresa García
García-Garre, Elisa
Vicente, Vicente
de la Peña, Francisco Ayala
author_facet García-Martínez, Elena
Gil, Ginés Luengo
Benito, Asunción Chaves
González-Billalabeitia, Enrique
Conesa, María Angeles Vicente
García, Teresa García
García-Garre, Elisa
Vicente, Vicente
de la Peña, Francisco Ayala
author_sort García-Martínez, Elena
collection PubMed
description INTRODUCTION: Tumor microenvironment immunity is associated with breast cancer outcome. A high lymphocytic infiltration has been associated with response to neoadjuvant chemotherapy, but the contribution to response and prognosis of immune cell subpopulations profiles in both pre-treated and post-treatment residual tumor is still unclear. METHODS: We analyzed pre- and post-treatment tumor-infiltrating immune cells (CD3, CD4, CD8, CD20, CD68, Foxp3) by immunohistochemistry in a series of 121 breast cancer patients homogeneously treated with neoadjuvant chemotherapy. Immune cell profiles were analyzed and correlated with response and survival. RESULTS: We identified three tumor-infiltrating immune cell profiles, which were able to predict pathological complete response (pCR) to neoadjuvant chemotherapy (cluster B: 58%, versus clusters A and C: 7%). A higher infiltration by CD4 lymphocytes was the main factor explaining the occurrence of pCR, and this association was validated in six public genomic datasets. A higher chemotherapy effect on lymphocytic infiltration, including an inversion of CD4/CD8 ratio, was associated with pCR and with better prognosis. Analysis of the immune infiltrate in post-chemotherapy residual tumor identified a profile (cluster Y), mainly characterized by high CD3 and CD68 infiltration, with a worse disease free survival. CONCLUSIONS: Breast cancer immune cell subpopulation profiles, determined by immunohistochemistry-based computerized analysis, identify groups of patients characterized by high response (in the pre-treatment setting) and poor prognosis (in the post-treatment setting). Further understanding of the mechanisms underlying the distribution of immune cells and their changes after chemotherapy may contribute to the development of new immune-targeted therapies for breast cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-014-0488-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4303200
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43032002015-01-23 Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer García-Martínez, Elena Gil, Ginés Luengo Benito, Asunción Chaves González-Billalabeitia, Enrique Conesa, María Angeles Vicente García, Teresa García García-Garre, Elisa Vicente, Vicente de la Peña, Francisco Ayala Breast Cancer Res Research Article INTRODUCTION: Tumor microenvironment immunity is associated with breast cancer outcome. A high lymphocytic infiltration has been associated with response to neoadjuvant chemotherapy, but the contribution to response and prognosis of immune cell subpopulations profiles in both pre-treated and post-treatment residual tumor is still unclear. METHODS: We analyzed pre- and post-treatment tumor-infiltrating immune cells (CD3, CD4, CD8, CD20, CD68, Foxp3) by immunohistochemistry in a series of 121 breast cancer patients homogeneously treated with neoadjuvant chemotherapy. Immune cell profiles were analyzed and correlated with response and survival. RESULTS: We identified three tumor-infiltrating immune cell profiles, which were able to predict pathological complete response (pCR) to neoadjuvant chemotherapy (cluster B: 58%, versus clusters A and C: 7%). A higher infiltration by CD4 lymphocytes was the main factor explaining the occurrence of pCR, and this association was validated in six public genomic datasets. A higher chemotherapy effect on lymphocytic infiltration, including an inversion of CD4/CD8 ratio, was associated with pCR and with better prognosis. Analysis of the immune infiltrate in post-chemotherapy residual tumor identified a profile (cluster Y), mainly characterized by high CD3 and CD68 infiltration, with a worse disease free survival. CONCLUSIONS: Breast cancer immune cell subpopulation profiles, determined by immunohistochemistry-based computerized analysis, identify groups of patients characterized by high response (in the pre-treatment setting) and poor prognosis (in the post-treatment setting). Further understanding of the mechanisms underlying the distribution of immune cells and their changes after chemotherapy may contribute to the development of new immune-targeted therapies for breast cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-014-0488-5) contains supplementary material, which is available to authorized users. BioMed Central 2014-11-29 2014 /pmc/articles/PMC4303200/ /pubmed/25432519 http://dx.doi.org/10.1186/s13058-014-0488-5 Text en © García-Martínez et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
García-Martínez, Elena
Gil, Ginés Luengo
Benito, Asunción Chaves
González-Billalabeitia, Enrique
Conesa, María Angeles Vicente
García, Teresa García
García-Garre, Elisa
Vicente, Vicente
de la Peña, Francisco Ayala
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
title Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
title_full Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
title_fullStr Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
title_full_unstemmed Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
title_short Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
title_sort tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303200/
https://www.ncbi.nlm.nih.gov/pubmed/25432519
http://dx.doi.org/10.1186/s13058-014-0488-5
work_keys_str_mv AT garciamartinezelena tumorinfiltratingimmunecellprofilesandtheirchangeafterneoadjuvantchemotherapypredictresponseandprognosisofbreastcancer
AT gilginesluengo tumorinfiltratingimmunecellprofilesandtheirchangeafterneoadjuvantchemotherapypredictresponseandprognosisofbreastcancer
AT benitoasuncionchaves tumorinfiltratingimmunecellprofilesandtheirchangeafterneoadjuvantchemotherapypredictresponseandprognosisofbreastcancer
AT gonzalezbillalabeitiaenrique tumorinfiltratingimmunecellprofilesandtheirchangeafterneoadjuvantchemotherapypredictresponseandprognosisofbreastcancer
AT conesamariaangelesvicente tumorinfiltratingimmunecellprofilesandtheirchangeafterneoadjuvantchemotherapypredictresponseandprognosisofbreastcancer
AT garciateresagarcia tumorinfiltratingimmunecellprofilesandtheirchangeafterneoadjuvantchemotherapypredictresponseandprognosisofbreastcancer
AT garciagarreelisa tumorinfiltratingimmunecellprofilesandtheirchangeafterneoadjuvantchemotherapypredictresponseandprognosisofbreastcancer
AT vicentevicente tumorinfiltratingimmunecellprofilesandtheirchangeafterneoadjuvantchemotherapypredictresponseandprognosisofbreastcancer
AT delapenafranciscoayala tumorinfiltratingimmunecellprofilesandtheirchangeafterneoadjuvantchemotherapypredictresponseandprognosisofbreastcancer